pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
GILEAD · news · pharmadog
← back to GILEAD
News mentioning GILEAD
74
stories
8h
STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
stat
3d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
5d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
5d
AbCellera, Vertex partner on next-gen T-cell engagers
biopharma dive
5d
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
endpoints
5d
GSK cost-cutting plan includes global layoffs
biospace
6d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
6d
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
fiercebiotech
7d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
7d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
7d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
8d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
10d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
10d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
10d
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
10d
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
fiercebiotech
11d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
11d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
11d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
11d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
11d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
12d
New study supports testing of Merck’s Ebola vaccine in DRC outbreak
stat
12d
Congo’s Ebola outbreak has killed over 1,000 people
stat
12d
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
12d
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
12d
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
13d
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
endpoints
14d
Recon: Novo sues Lilly over weight-loss drug ads; Gilead, Merck say HIV pill keeps HIV suppressed in two Phase 3 trials
raps
15d
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
18d
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
← prev
page 1 of 3
next →
